BioLineRx Ratios (2023-2025) | BLRX

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Profitability
Gross Margin 78.77%83.37%83.37%48.17%86.67%76.32%80.33%
EBT Margin -855.34%-641.59%-1,376.34%2,092.06%-56.79%-68.38%-76.11%0.46%-772.94%-666.78%-445.67%
EBIT Margin -955.34%-741.59%-1,476.34%1,992.06%-70.34%-107.05%-108.98%-37.67%-937.65%-757.57%-516.86%
EBITDA Margin -1,311.97%1,387.06%-1,476.34%1,992.06%-10.15%8.97%-117.78%-37.67%2,010.59%-1,296.05%-228.81%
Operating Margin -955.34%-741.59%-1,476.34%1,992.06%-70.34%-107.05%-108.98%-37.67%-937.65%-757.57%-516.86%
Net Margin -855.34%-641.59%-1,376.34%2,092.06%-56.79%-68.38%-76.11%0.46%-772.94%-666.78%-445.67%
FCF Margin -861.27%-719.15%-1,182.80%-512.34%-205.35%-209.57%-198.77%-74.24%-1,016.08%-58.22%-493.21%
Efficiency
Inventory Average 1.65M2.42M3.26M3.59M3.34M3.23M3.08M2.52M
Assets Average 63.79M55.90M58.39M57.76M58.10M58.67M45.82M41.21M43.39M41.54M
Equity Average -351.43M-368.71M6.94M-0.35M-391.06M-393.73M-197.47M-196.50M1.97M-0.49M
Invested Capital -339.60M-357.62M-373.64M393.75M-387.62M-380.16M-386.82M6.17M-390.02M403.12M-395.14M
Asset Utilization Ratio 0.040.140.210.280.630.540.400.31
Leverage & Solvency
Interest Coverage Ratio 9.557.4214.76-19.925.192.773.320.995.698.347.26
Debt to Equity -0.03-0.03-0.030.03-0.02-0.08-0.077.95-0.030.03-0.03
Debt Ratio 0.160.200.220.150.190.460.530.350.280.260.25
Equity Ratio -4.98-6.12-7.136.11-7.58-6.05-7.520.04-9.079.21-10.04
Times Interest Earned 9.557.4214.76-19.925.192.773.320.995.698.347.26
Valuation
Enterprise Value 33.21M64.04M68.26M54.25M58.42M3.00M-10.66M-2.45M-2.15M-11.15M-10.28M
Market Capitalization 54.55M98.14M111.99M97.24M81.13M41.28M42.80M17.11M11.01M17.00M14.93M
Return Ratios
Return on Sales -21.91%-5.37%-3.18%-1.90%-0.39%-0.42%-0.45%-0.46%
Return on Capital Employed -3.18%-1.73%-1.51%-1.02%-0.67%-0.66%-0.52%-0.41%
Return on Assets -0.81%-0.75%-0.66%-0.53%-0.25%-0.23%-0.18%-0.14%
Return on Equity -6.85%124.97%0.10%0.08%0.06%0.05%-3.91%11.97%